Last reviewed · How we verify
Radiprodil oral
At a glance
| Generic name | Radiprodil oral |
|---|---|
| Also known as | UCB3491 |
| Sponsor | UCB Biopharma S.P.R.L. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Open-Label Study of Radiprodil Pharmacokinetics, Safety, and Tolerability in Hepatically Impaired Participants (PHASE1)
- Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder (PHASE3)
- Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults (PHASE1)
- Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II (PHASE1, PHASE2)
- Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder (PHASE1)
- Study to Evaluate Properties of Radiprodil Given in Oral Solution to Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radiprodil oral CI brief — competitive landscape report
- Radiprodil oral updates RSS · CI watch RSS
- UCB Biopharma S.P.R.L. portfolio CI